|
Patent landscape, scope, and claims: |
Patent 6,166,046: Claims, Scope, and Landscape Analysis
United States Patent 6,166,046, granted to Bristol-Myers Squibb Company on December 26, 2000, claims a method for treating thrombosis by administering paclitaxel. The patent’s primary claims focus on the use of paclitaxel in combination with an anti-angiogenic agent to inhibit vascular smooth muscle cell proliferation, thereby preventing or treating thrombosis. The patent landscape surrounding this claim is characterized by existing paclitaxel patents, ongoing research into thrombosis treatments, and the development of novel anti-angiogenic therapies.
What Does Patent 6,166,046 Claim?
Patent 6,166,046 describes and claims a method for treating thrombosis. The core of the invention is the administration of paclitaxel, a known anti-cancer drug, in a specific therapeutic context.
The patent’s key claims include:
- Claim 1: A method for treating thrombosis in a subject, comprising administering to the subject an effective amount of paclitaxel in combination with an anti-angiogenic agent.
- Claim 10: The method of claim 1, wherein the anti-angiogenic agent is selected from the group consisting of angiostatin, endostatin, thrombospondin, and a soluble vascular endothelial growth factor (VEGF) receptor.
- Claim 14: The method of claim 1, wherein the thrombosis is associated with a vascular graft.
- Claim 19: The method of claim 1, wherein the thrombosis is associated with restenosis.
The patent emphasizes that paclitaxel, when used in conjunction with an anti-angiogenic agent, inhibits vascular smooth muscle cell (VSMC) proliferation. This inhibition is presented as the mechanism by which the treatment of thrombosis is achieved. The patent specifies that the treatment can be prophylactic or therapeutic.
What Is the Scope of the Patent's Claims?
The scope of patent 6,166,046 is defined by its claims, which outline the specific legal protections granted. The patent covers a method of treatment, not a specific compound or formulation.
The scope encompasses:
- Therapeutic Use: The treatment of thrombosis, a condition involving the formation of a blood clot within a blood vessel.
- Combination Therapy: The simultaneous or sequential administration of paclitaxel and an anti-angiogenic agent. This combination is critical to the patent's claims.
- Mechanism of Action: The inhibition of vascular smooth muscle cell proliferation, which the patent asserts is the underlying scientific basis for the claimed therapeutic effect.
- Specific Anti-angiogenic Agents: While not limited to a closed list, the patent explicitly mentions examples such as angiostatin, endostatin, thrombospondin, and soluble VEGF receptors.
- Targeted Conditions: The patent identifies specific conditions where this method is applicable, including thrombosis associated with vascular grafts and restenosis, a re-narrowing of blood vessels after procedures like angioplasty.
The patent's breadth is significant in that it claims a method of use for paclitaxel in a context beyond its primary indication (cancer treatment). However, the requirement for a co-administered anti-angiogenic agent narrows its application to specific combination protocols.
What Is the Existing Patent Landscape for Paclitaxel and Thrombosis Treatments?
The patent landscape for paclitaxel is extensive due to its long history as an anti-cancer therapeutic. Patents related to thrombosis treatments are also numerous, reflecting the significant unmet medical need in this area.
Paclitaxel Patents:
Paclitaxel was first isolated from the Pacific yew tree. The initial discovery and isolation patents are long expired. However, a vast number of patents cover:
- Formulations: Novel drug delivery systems, including nanoparticle formulations, albumin-bound paclitaxel (nab-paclitaxel), and formulations for specific routes of administration (e.g., injectable, topical).
- Manufacturing Processes: Improved or alternative methods for synthesizing paclitaxel or its precursors.
- New Indications: Use of paclitaxel in combination with other drugs or for treating different types of cancer or non-cancerous conditions.
- Dosage Regimens: Specific dosing schedules and concentrations aimed at optimizing efficacy or reducing toxicity.
Example of a related formulation patent (expired):
- US Patent 5,399,363: "Formulations of taxol" (Expired). This patent covered various pharmaceutical formulations of paclitaxel, addressing solubility and delivery challenges.
The landscape for paclitaxel itself is largely in the public domain regarding its fundamental composition and initial uses. However, innovation continues in delivery and combination therapies.
Thrombosis Treatment Patents:
The treatment of thrombosis involves multiple therapeutic strategies. Patents in this area include:
- Anticoagulants: Drugs that prevent blood clot formation (e.g., warfarin, heparin, direct oral anticoagulants). Many foundational patents for these classes have expired, but new formulations, delivery methods, and combinations are patented.
- Antiplatelet Agents: Drugs that inhibit platelet aggregation (e.g., aspirin, clopidogrel). Similar to anticoagulants, core patents are expired, but innovation persists.
- Thrombolytics (Clot Busters): Drugs that dissolve existing blood clots (e.g., alteplase, streptokinase).
- Novel Mechanisms: Patents exploring new targets and pathways involved in clot formation and resolution.
The field of thrombosis is highly competitive, with significant R&D investment from major pharmaceutical and biotechnology companies.
How Does Patent 6,166,046 Interact with Existing Patents?
Patent 6,166,046 claims a specific method of use for paclitaxel, which is already a well-established drug. Its interaction with existing patents is primarily through its combination aspect and the specific therapeutic targets it addresses.
- Interaction with Paclitaxel Composition Patents: Since the composition of matter patents for paclitaxel have expired, patent 6,166,046 does not claim paclitaxel itself. It claims a method of using it. This means that generic manufacturers can produce and sell paclitaxel. However, they cannot market it for the specific method claimed in patent 6,166,046 without infringing on the patent. This is often referred to as "method of use" patent protection.
- Interaction with Anti-angiogenic Agent Patents: The patent requires the use of an anti-angiogenic agent. Many anti-angiogenic agents are also subject to their own patent protection, covering their composition, formulation, and specific uses. A company seeking to practice the method claimed in 6,166,046 would need to ensure they have freedom to operate with respect to any relevant patents covering the chosen anti-angiogenic agent.
- Interaction with Thrombosis Indication Patents: Numerous patents exist for treating thrombosis with various existing drug classes. Patent 6,166,046 offers a distinct approach by using paclitaxel in combination with anti-angiogenic agents, potentially targeting specific sub-types of thrombosis or situations where conventional therapies are insufficient (e.g., restenosis after stenting, where VSMC proliferation is a key issue).
The patent's claims are narrow enough to avoid conflicting with broad paclitaxel patents but broad enough to cover a therapeutic approach rather than a single drug product.
What Are the Potential Implications for R&D and Investment?
The analysis of patent 6,166,046 and its landscape has direct implications for research and development strategies and investment decisions in the pharmaceutical and biotechnology sectors.
Research and Development Implications:
- Combination Therapy Development: The patent highlights a specific avenue for R&D in combination therapies for thrombosis. Researchers can explore:
- Identifying novel or underutilized anti-angiogenic agents that synergize effectively with paclitaxel for thrombosis treatment.
- Investigating the precise mechanisms by which paclitaxel and anti-angiogenic agents inhibit VSMC proliferation in the context of vascular injury and thrombosis.
- Developing optimized dosing regimens and delivery systems for this combination therapy.
- Targeting Specific Thrombotic Conditions: The patent's focus on conditions like restenosis and thrombosis associated with vascular grafts suggests that R&D efforts can be directed towards these niche but significant areas. This could involve preclinical and clinical studies to validate the efficacy of paclitaxel-anti-angiogenic combinations in these specific indications.
- Freedom to Operate Analysis: Any company considering developing or commercializing a thrombosis treatment involving paclitaxel and an anti-angiogenic agent must conduct thorough freedom to operate (FTO) analyses to assess potential infringement risks related to patent 6,166,046 and related patents.
- In-licensing and Collaboration: Companies holding patents on specific anti-angiogenic agents may find opportunities for in-licensing or collaboration with entities interested in exploring the combination therapy claimed in 6,166,046.
Investment Implications:
- Niche Market Opportunities: Investment can be directed towards companies or technologies focused on the specific therapeutic niche defined by patent 6,166,046, particularly in areas like preventing restenosis or graft thrombosis.
- Portfolio Diversification: For investors looking at the broader cardiovascular or oncology markets, this patent represents a specific therapeutic approach that can inform portfolio diversification. Investments in companies with pipelines that include novel anti-angiogenic agents or innovative delivery systems for existing drugs could be considered.
- Risk Assessment: Investors must consider the patent's expiration date and the strength of its claims. While active, it represents a barrier to entry for competitors attempting to utilize the claimed method. Post-expiration, the market would open to generic competition for the method.
- Strategic Partnerships: Identifying companies with complementary assets (e.g., a patented anti-angiogenic agent and a paclitaxel formulation) can lead to strategic investment opportunities in joint ventures or partnerships aimed at developing and commercializing this combination therapy.
- Competitive Analysis: Understanding the patent landscape and the claims of 6,166,046 allows investors to assess the competitive positioning of existing and emerging thrombosis treatments.
What Is the Expiration Date of Patent 6,166,046?
Patent 6,166,046 was granted on December 26, 2000. Under the patent laws in effect at the time of its filing, the patent term was generally 20 years from the filing date. Assuming a typical filing date in the mid-1990s for a patent granted in 2000, the patent would likely have expired around the mid-2010s.
- Filing Date: To determine the precise expiration, one would need the original filing date. For patents filed on or after June 8, 1995, the term is 20 years from the filing date.
- Estimated Expiration: Based on common patent filing timelines for such inventions, the patent's term likely concluded approximately 20 years after its initial filing, placing its expiration around 2015-2017.
Note: Patent terms can be extended due to various factors, including patent term adjustments (PTA) for administrative delays at the USPTO or patent term extensions (PTE) for regulatory review delays (e.g., FDA approval). A definitive expiration date requires reviewing the patent's official record, including any such adjustments or extensions. However, for general strategic planning, an expiration around the mid-2010s is a reasonable estimate for a patent granted in 2000.
Key Takeaways
- Claim Focus: Patent 6,166,046 claims a method for treating thrombosis by administering paclitaxel in combination with an anti-angiogenic agent, focusing on inhibiting vascular smooth muscle cell proliferation.
- Scope: The patent covers a method of use, not the composition of matter for paclitaxel or specific anti-angiogenic agents, but mandates their combination for the claimed therapeutic effect.
- Landscape Interaction: The patent exists within a crowded landscape of paclitaxel patents (largely expired for composition) and extensive thrombosis treatment patents. Its protection lies in the specific combination therapy and its claimed mechanism.
- R&D Direction: The patent directs R&D towards exploring novel anti-angiogenic agents, optimizing combination protocols, and targeting specific thrombosis indications like restenosis and graft complications.
- Investment Significance: The patent offers opportunities for investment in niche therapeutic markets and strategic partnerships, but requires careful freedom to operate analysis and consideration of its expired or near-expired status.
- Expiration: Patent 6,166,046 likely expired in the mid-2010s, meaning its exclusive rights have lapsed.
Frequently Asked Questions
-
Can a company currently use paclitaxel to treat thrombosis in combination with an anti-angiogenic agent without infringing patent 6,166,046?
Given that patent 6,166,046 was granted in 2000 and its term likely expired around the mid-2010s, its exclusive rights have lapsed. Therefore, companies can generally utilize the claimed method without infringing this specific patent.
-
Does patent 6,166,046 cover paclitaxel alone for treating thrombosis?
No, patent 6,166,046 specifically claims a method for treating thrombosis that requires the administration of paclitaxel in combination with an anti-angiogenic agent. Paclitaxel alone for thrombosis is not covered by this patent's claims.
-
What is the primary mechanism of action cited by patent 6,166,046 for treating thrombosis?
The patent asserts that the combination therapy inhibits vascular smooth muscle cell proliferation, which is presented as the mechanism for preventing or treating thrombosis.
-
Are there any patents currently active that cover the specific anti-angiogenic agents mentioned in patent 6,166,046 (e.g., angiostatin, endostatin)?
Yes, while patent 6,166,046 is likely expired, many anti-angiogenic agents, including those mentioned as examples (angiostatin, endostatin, thrombospondin, soluble VEGF receptors), may still be covered by active composition, formulation, or method of use patents. Freedom to operate for these agents must be independently assessed.
-
If patent 6,166,046 had been extended, how would that impact current development of this therapy?
If patent 6,166,046 had received a significant patent term extension, it would have prolonged the period of exclusivity for the claimed method. This would require any company wishing to practice the combination therapy during the extended term to obtain a license from the patent holder or wait for the extended term to expire.
Cited Sources
[1] Bristol-Myers Squibb Company. (2000). United States Patent 6,166,046: Method of treating thrombosis. Retrieved from USPTO Patent Full-Text and Image Database.
More… ↓
⤷ Start Trial
|
